H2.0类同源异型盒在癌症发生发展中的潜在双重作用及其预后价值。

IF 2.7 4区 医学 Q2 Medicine Canadian Journal of Gastroenterology and Hepatology Pub Date : 2023-09-09 eCollection Date: 2023-01-01 DOI:10.1155/2023/5521544
Shuo Chen, Lin Zhang, Kai Wang, Jizhen Huo, Siqi Zhang, Xipeng Zhang
{"title":"H2.0类同源异型盒在癌症发生发展中的潜在双重作用及其预后价值。","authors":"Shuo Chen,&nbsp;Lin Zhang,&nbsp;Kai Wang,&nbsp;Jizhen Huo,&nbsp;Siqi Zhang,&nbsp;Xipeng Zhang","doi":"10.1155/2023/5521544","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong><i>H2.0-like homeobox</i> (<i>HLX</i>) is highly expressed in several hematopoietic malignancies. However, the role of <i>HLX</i> in the carcinogenesis and progression of colorectal cancer (CRC) patients has rarely been reported.</p><p><strong>Methods: </strong>In this study, the data were collected from The Cancer Genome Atlas and Gene Expression Omnibus databases. The diagnostic value of <i>HLX</i> was analyzed by the R package \"pROC.\" The overall survival was estimated using the \"survival\" and \"survminer\" packages. A nomogram was established to predict 1-, 3-, and 5-year overall survival of CRC patients. The CIBERSORT software was employed to calculate the relative proportions of 22 immune cells.</p><p><strong>Results: </strong><i>HLX</i> expression was downregulated in CRC patients. Remarkably, <i>HLX</i> expression was increased with stage (stage I-stage III) of CRC, and the CRC patients with high <i>HLX</i> expression exhibited a poor prognosis. The promoter methylation level of <i>HLX</i> was prominently increased in CRC samples compared to paracancerous samples. We also found that the six miRNAs target <i>HLX</i> genes, leading to its downregulation, and <i>HLX</i> expression had a negative correlation with its downstream target gene <i>BRI3BP</i> in both CRC and normal samples. Finally, we found that the 12 immune infiltrating cells were observably different between high and low <i>HLX</i> expression groups. The <i>HLX</i> had a significant positive correlation with 8 immune checkpoints (PD-1 (PDCD1), CTLA4, PDL-1 (CD274), PDL-2 (PDCD1LG2), CD80, CD86, LAG3, and TIGIT) expressions.</p><p><strong>Conclusion: </strong><i>HLX</i> probably played a carcinostasis role in the early stages of CRC but exhibited a cancer-promoting effect in the advanced stages. Meanwhile, <i>HLX</i> could serve as a reliable prognostic indicator for CRC.</p>","PeriodicalId":48755,"journal":{"name":"Canadian Journal of Gastroenterology and Hepatology","volume":null,"pages":null},"PeriodicalIF":2.7000,"publicationDate":"2023-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505080/pdf/","citationCount":"0","resultStr":"{\"title\":\"The Potential Dual Role of H2.0-like Homeobox in the Tumorgenesis and Development of Colorectal Cancer and Its Prognostic Value.\",\"authors\":\"Shuo Chen,&nbsp;Lin Zhang,&nbsp;Kai Wang,&nbsp;Jizhen Huo,&nbsp;Siqi Zhang,&nbsp;Xipeng Zhang\",\"doi\":\"10.1155/2023/5521544\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong><i>H2.0-like homeobox</i> (<i>HLX</i>) is highly expressed in several hematopoietic malignancies. However, the role of <i>HLX</i> in the carcinogenesis and progression of colorectal cancer (CRC) patients has rarely been reported.</p><p><strong>Methods: </strong>In this study, the data were collected from The Cancer Genome Atlas and Gene Expression Omnibus databases. The diagnostic value of <i>HLX</i> was analyzed by the R package \\\"pROC.\\\" The overall survival was estimated using the \\\"survival\\\" and \\\"survminer\\\" packages. A nomogram was established to predict 1-, 3-, and 5-year overall survival of CRC patients. The CIBERSORT software was employed to calculate the relative proportions of 22 immune cells.</p><p><strong>Results: </strong><i>HLX</i> expression was downregulated in CRC patients. Remarkably, <i>HLX</i> expression was increased with stage (stage I-stage III) of CRC, and the CRC patients with high <i>HLX</i> expression exhibited a poor prognosis. The promoter methylation level of <i>HLX</i> was prominently increased in CRC samples compared to paracancerous samples. We also found that the six miRNAs target <i>HLX</i> genes, leading to its downregulation, and <i>HLX</i> expression had a negative correlation with its downstream target gene <i>BRI3BP</i> in both CRC and normal samples. Finally, we found that the 12 immune infiltrating cells were observably different between high and low <i>HLX</i> expression groups. The <i>HLX</i> had a significant positive correlation with 8 immune checkpoints (PD-1 (PDCD1), CTLA4, PDL-1 (CD274), PDL-2 (PDCD1LG2), CD80, CD86, LAG3, and TIGIT) expressions.</p><p><strong>Conclusion: </strong><i>HLX</i> probably played a carcinostasis role in the early stages of CRC but exhibited a cancer-promoting effect in the advanced stages. Meanwhile, <i>HLX</i> could serve as a reliable prognostic indicator for CRC.</p>\",\"PeriodicalId\":48755,\"journal\":{\"name\":\"Canadian Journal of Gastroenterology and Hepatology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2023-09-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505080/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Canadian Journal of Gastroenterology and Hepatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1155/2023/5521544\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian Journal of Gastroenterology and Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2023/5521544","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

背景:H2.0样同源盒(HLX)在多种造血系统恶性肿瘤中高度表达。然而,HLX在癌症(CRC)患者的致癌和进展中的作用很少报道。方法:本研究数据来源于癌症基因组图谱和基因表达综合数据库。HLX的诊断价值通过R软件包“pROC”进行分析。总生存率通过“生存率”和“生存矿工”软件包进行估计。建立列线图来预测CRC患者的1年、3年和5年总生存率。CIBERSORT软件用于计算22个免疫细胞的相对比例。结果:CRC患者HLX表达下调。值得注意的是,HLX的表达随着CRC的分期(I-III期)而增加,并且HLX高表达的CRC患者表现出较差的预后。与癌旁样本相比,CRC样本中HLX的启动子甲基化水平显著增加。我们还发现,六种miRNA靶向HLX基因,导致其下调,并且在CRC和正常样本中,HLX的表达与其下游靶基因BRI3BP呈负相关。最后,我们发现HLX高表达组和低表达组的12个免疫浸润细胞存在显著差异。HLX与8个免疫检查点(PD-1(PDCD1)、CTLA4、PDL-1(CD274)、PDL-2(PDCD1LG2)、CD80、CD86、LAG3和TIGIT)的表达呈显著正相关。结论:HLX可能在CRC早期起到抑癌作用,但在晚期起到促癌作用。同时,HLX可作为CRC的可靠预后指标。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
The Potential Dual Role of H2.0-like Homeobox in the Tumorgenesis and Development of Colorectal Cancer and Its Prognostic Value.

Background: H2.0-like homeobox (HLX) is highly expressed in several hematopoietic malignancies. However, the role of HLX in the carcinogenesis and progression of colorectal cancer (CRC) patients has rarely been reported.

Methods: In this study, the data were collected from The Cancer Genome Atlas and Gene Expression Omnibus databases. The diagnostic value of HLX was analyzed by the R package "pROC." The overall survival was estimated using the "survival" and "survminer" packages. A nomogram was established to predict 1-, 3-, and 5-year overall survival of CRC patients. The CIBERSORT software was employed to calculate the relative proportions of 22 immune cells.

Results: HLX expression was downregulated in CRC patients. Remarkably, HLX expression was increased with stage (stage I-stage III) of CRC, and the CRC patients with high HLX expression exhibited a poor prognosis. The promoter methylation level of HLX was prominently increased in CRC samples compared to paracancerous samples. We also found that the six miRNAs target HLX genes, leading to its downregulation, and HLX expression had a negative correlation with its downstream target gene BRI3BP in both CRC and normal samples. Finally, we found that the 12 immune infiltrating cells were observably different between high and low HLX expression groups. The HLX had a significant positive correlation with 8 immune checkpoints (PD-1 (PDCD1), CTLA4, PDL-1 (CD274), PDL-2 (PDCD1LG2), CD80, CD86, LAG3, and TIGIT) expressions.

Conclusion: HLX probably played a carcinostasis role in the early stages of CRC but exhibited a cancer-promoting effect in the advanced stages. Meanwhile, HLX could serve as a reliable prognostic indicator for CRC.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.80
自引率
0.00%
发文量
0
审稿时长
37 weeks
期刊介绍: Canadian Journal of Gastroenterology and Hepatology is a peer-reviewed, open access journal that publishes original research articles, review articles, and clinical studies in all areas of gastroenterology and liver disease - medicine and surgery. The Canadian Journal of Gastroenterology and Hepatology is sponsored by the Canadian Association of Gastroenterology and the Canadian Association for the Study of the Liver.
期刊最新文献
Acute Variceal Hemorrhage in Germany-A Nationwide Study of 65,357 Hospitalized Cases: Variceal Hemorrhage in Germany. The Predictive Value of Time-Varying Noninvasive Scores on Long-Term Prognosis of NAFLD in South Korea. Feasibility and Acceptability of Antenatal Hepatitis C Screening: A Pilot Study. Primary Care Support Tools for Digestive Health Care: A Mixed Method Study. Long-Term Treatment with Bulevirtide in Patients with Chronic Hepatitis D and Advanced Chronic Liver Disease.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1